How did Gilead Sciences' revenue and expenses perform in Q4 2024?

Gilead Sciences reported $144 million in revenue from its Royalty, Contract, and Other business segments in Q4 2024. The company's operating expenses were $1.78 billion for the same period, highlighting the importance of managing costs in relation to its revenue streams. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |GILD|GILD.O|Gilead Sciences|20240101-2024|Royalty,Contract and Other|1.44E8|185| |GILD|GILD.O|Gilead Sciences|20240101-2024|Royalty,Contract and Other|1.11E8|185| |GILD|GILD.O|Gilead Sciences|20240101-2024|Royalty,Contract and Other|8.1E7|185| |GILD|GILD.O|Gilead Sciences|20240101-2024|Royalty,Contract and Other|3.9E7|185| |GILD|GILD.O|Gilead Sciences|20240101-2024|Royalty,Contract and Other|3.9E7|185| |GILD|GILD.O|Gilead Sciences|20240101-2024|Product|6.647E9|185| |code|Ticker|Name|Date|Net Income YoY|Net Income|market_code| |---|---|---|---|---|---|---| |GILD|GILD.O|Gilead Sciences|2024 Q1|-523.3502538071066|-4.17E9|185| |GILD|GILD.O|Gilead Sciences|2024 Q2|55.34167468719923|1.614E9|185| |GILD|GILD.O|Gilead Sciences|2024 Q3|-42.31123388581952|1.253E9|185| |GILD|GILD.O|Gilead Sciences|2024 Q4|25.82921665490473|1.783E9|185|